Published recently in Translational Psychiatry, the study led by Donegan, Hossein, Panny, and colleagues meticulously evaluated whether these commonly deployed interventions modulate model-based decision-making. Their findings are both surprising and provocative: none of the treatments, including rapid-acting ketamine, classic antidepressants, or iCBT, significantly altered model-based planning capabilities in individuals diagnosed with major depression. This challenges prevailing theories that link therapeutic efficacy directly with enhancements in goal-directed cognitive control. Instead, it suggests that the cognitive substrates of decision-making implicated in depression may remain remarkably stable despite symptomatic relief.

To contextualize these findings, it is essential to understand the distinction between model-based and model-free planning. Model-free strategies rely on habitual, experience-driven responses without flexible adaptation, whereas model-based strategies invoke an internal cognitive map to forecast the consequences of actions. Prior neuroimaging studies have implicated disrupted model-based planning in depression, positing this as a potential mechanism underlying the indecisiveness and anhedonia common in affected patients. However, this latest research injects nuance into this framework by demonstrating that effective clinical improvement does not necessarily translate into restored model-based planning performance.

The research team recruited a large cohort of depressed patients undergoing treatment with selective serotonin reuptake inhibitors (SSRIs), ketamine infusions—a novel glutamatergic agent—and those engaged in a structured iCBT program delivered via internet platforms. Through rigorous longitudinal assessment employing decision-making tasks specifically designed to dissect model-based and model-free control, the investigators quantified planning performance before and after treatment intervention. The robustness of the experimental design—including appropriate control groups, standardized clinical assessments, and comprehensive cognitive testing—underscored the reliability of the observations.

Intriguingly, the study’s results eradicate the assumption that ketamine’s rapid antidepressant effects, often linked to synaptogenesis and neuroplasticity enhancement, confer immediate cognitive gains in flexible planning domains. Despite ketamine’s potent mechanistic action at NMDA receptors and its known rapid alleviation of depressive symptoms, patients did not demonstrate enhanced abilities in simulating future action outcomes post-treatment. This outcome adds to a growing body of evidence suggesting a dissociation between mood symptom alleviation and underlying cognitive processes.

Similarly, antidepressants such as SSRIs, which primarily modulate monoaminergic neurotransmission, failed to exhibit substantive changes in model-based control after weeks of treatment. This finding may imply that the benefits of these pharmacotherapies in mood stabilization occur through pathways largely independent of the executive cognitive functions driving model-based decisions. Such independence raises critical questions about the precise cognitive targets of these treatments and how they relate to broader functional recovery in depression.

The inclusion of internet-delivered cognitive behavioral therapy broadens the scope of inquiry to non-pharmacological interventions. iCBT has revolutionized accessibility to evidence-based psychotherapy, offering scalable treatment options. However, the study revealed that even this manualized cognitive restructuring intervention did not measurably shift model-based planning. While iCBT is effective in symptom reduction, its impact might lie more in modifying maladaptive thought patterns and emotional regulation rather than recalibrating complex forward-planning faculties.

Additionally, the preservation of model-based planning despite clinical improvement raises intriguing possibilities about compensatory mechanisms. It may be that other cognitive domains or neural circuits not measured in this study mediate the benefits seen in depression treatment. Alternatively, the severities or subtypes of depression sampled might inherently retain intact goal-directed control, suggesting a need for more nuanced phenotyping when investigating cognitive remediation in mood disorders.

These insights have significant implications for both clinical practice and future research directions. For clinicians, understanding that antidepressant and ketamine treatments plus iCBT do not necessarily restore model-based planning can temper expectations around cognitive improvement following symptomatic amelioration. Moreover, it highlights unmet therapeutic needs—specifically cognitive interventions directly targeting decision-making processes might be warranted for holistic recovery in depression.

For neuroscientists and psychiatric researchers, this work opens fertile ground in exploring alternative or adjunctive therapies aimed at cognitive enhancement. Investigating pharmacological compounds or behavioral interventions that more directly target prefrontal-striatal circuits underlying model-based planning could unlock new avenues for treatment-resistant cognitive symptoms in depression. Longitudinal studies integrating neuroimaging, computational modeling, and ecological momentary assessment will be critical in dissecting the complex interplay between mood, cognition, and neurobiology.

Furthermore, the study underscores the crucial role of rigorous model-based experimental paradigms in psychiatry. By leveraging sophisticated tasks that isolate latent cognitive mechanisms, researchers can more accurately pinpoint which domains remain impaired and which remain resilient throughout the course of mental illness and treatment. This precision medicine approach promises to revolutionize psychiatric diagnostics and therapeutics.

While definitive conclusions require replication and extension across diverse populations, including varying depression severities and comorbidities, these findings constitute a pivotal step forward. They provoke a reevaluation of entrenched assumptions regarding cognitive recovery trajectories in depression and challenge the field to expand therapeutic frameworks beyond mere symptom remission toward cognitive restoration.

In sum, this landmark study illuminates the complex, and sometimes counterintuitive, landscape of cognitive function in depression treatment. Although ketamine, antidepressants, and internet-delivered CBT effectively reduce depressive symptoms, they do not seem to directly improve model-based planning capabilities. This disconnect invites a paradigm shift in how we conceptualize and measure cognitive health in mood disorders, urging a broader integration of nuanced neurocognitive assessments in clinical trials and practice.

As we enter an era where mental health treatments are increasingly personalized and neurobiologically informed, understanding the dissociations among symptomatic, cognitive, and functional recovery becomes paramount. Continuing to unravel these threads will ultimately facilitate development of targeted interventions that restore not only mood but also the complex cognitive architectures that enable adaptive, goal-directed human behavior.

Subject of Research: Cognitive effects of depression treatments on model-based planning

Article Title: Model-based planning is unaffected by ketamine, antidepressant and internet delivered cognitive behavioural therapy treatments in depression

Article References:
Donegan, K.R., Hossein, S., Panny, B.M. et al. Model-based planning is unaffected by ketamine, antidepressant and internet delivered cognitive behavioural therapy treatments in depression. Transl Psychiatry 15, 505 (2025). https://doi.org/10.1038/s41398-025-03722-8

Image Credits: AI Generated

DOI: 10.1038/s41398-025-03722-8

The study delves deeply into the concept of intra-subject variability, a phenomenon describing fluctuations in behavioral responses observed within the same person over time. While variability is a natural component of human behavior, excessive fluctuations—particularly in the domain of reward processing—may underpin the erratic nature of symptoms experienced by patients with schizophrenia. Reward behavior, fundamentally tied to motivation and decision-making, reflects the brain’s capacity to evaluate gains and losses, integral to adaptive functioning and mental health.

Chen and colleagues employed sophisticated experimental paradigms designed to capture minute-to-minute changes in reward-seeking and reward-responding behaviors in individuals diagnosed with schizophrenia, comparing these fluctuations against healthy controls. This methodology enabled the researchers to quantify how seemingly subtle shifts in reward-based actions correlate with the breadth and intensity of psychotic and negative symptoms. Their results reveal an unprecedented link: patients exhibiting higher variability in reward responses typically reported more severe clinical manifestations, including hallucinations, delusions, and social withdrawal.

The significance of this discovery lies in the potential it holds for redefining symptom measurement in schizophrenia. Traditional clinical assessments often rely on static snapshots provided by questionnaires or clinician ratings, which might overlook underlying dynamical processes in cognition and behavior. By integrating intra-subject variability analyses, clinicians could obtain more sensitive and continuous indices reflecting ongoing pathological changes, thus enabling real-time symptom tracking and adjustment of therapeutic interventions.

At the neurobiological level, reward processing involves complex circuits predominantly anchored in the mesolimbic dopamine system and interconnected prefrontal regions. Dysregulation in dopamine transmission is a core theme in schizophrenia etiopathogenesis. The observed behavioral variability might mirror perturbed neural signaling and synaptic plasticity in these circuits. Specifically, inconsistent dopamine release or receptor sensitivity could result in erratic reward evaluation, undermining patients’ ability to stabilize motivation and goal-directed actions, thereby exacerbating their symptom profile.

Further supporting this interpretation, Chen et al.’s data suggest that intra-subject variability may serve as a proxy for neural noise or circuit instability, phenomena increasingly recognized as integral to schizophrenia’s pathophysiology. This framework posits that schizophrenia symptoms do not merely arise from static deficits but are propelled by dynamic disruptions impairing the brain’s capacity to filter and integrate information reliably over time. Such conceptual advances emphasize the disorder’s complexity and the need for temporally rich investigative tools.

Beyond pathophysiology, these findings have profound implications for therapeutic innovation. Existing pharmacological treatments mainly target dopamine receptor antagonism, providing symptomatic relief with limited effects on motivational deficits or negative symptoms. By identifying variability in reward-related behaviors as a marker of disease activity, clinicians could eventually tailor treatments designed to stabilize neural circuits and reduce behavioral volatility. Emerging neuromodulatory interventions or cognitive training protocols might be adapted to enhance reward system stability, an enticing target for future research.

Moreover, the study’s longitudinal design strengthens the causal inferences between behavioral variability and symptom evolution. Tracking patients over time revealed that increases in intra-subject variability often preceded clinical deterioration, suggesting a predictive role. This carries enormous potential for preemptive clinical management, whereby rising behavioral inconsistency could trigger intensified monitoring or early intervention, ultimately improving patient outcomes and reducing disease burden.

Equally important is the study’s contribution to the evolving notion of personalized psychiatry. Recognizing the heterogeneity of schizophrenia, with its diverse symptom clusters and trajectories, demands nuanced biomarkers. Reward behavior variability could form a core component of this biomarker set, facilitating stratification of patients based on mechanistic dysfunctions rather than symptomatic phenotypes alone. This paradigm shift aligns with broader trends in psychiatry aiming to enhance precision diagnostics and precision therapeutics.

In terms of methodology, the investigators combined advanced computational techniques, including variational analysis and time-series modeling, to robustly characterize intra-subject fluctuations. Their multi-modal assessment strategy, integrating behavioral tasks with clinical rating scales, exemplifies a rigorous approach to bridging the gap between experimental neuroscience and clinical psychiatry. These tools not only quantify variability but can be adapted for deployment in wearable or app-based monitoring platforms, heralding a new era of digital phenotyping for mental health.

This research also opens intriguing avenues for comparing schizophrenia with other neuropsychiatric disorders characterized by reward-processing abnormalities, such as bipolar disorder or major depressive disorder. Disentangling whether increased behavioral variability is specific to schizophrenia or a transdiagnostic marker could refine diagnostic boundaries and foster novel cross-disorder therapeutic strategies. Furthermore, exploring genetic and environmental modulators of this variability may elucidate vulnerability factors underlying symptom exacerbation.

Notably, the paper by Chen and colleagues underlines the importance of considering intra-individual dynamics not just as noise but as an informative signal carrying essential insights about brain and behavior relationships in schizophrenia. This paradigm challenges classical static diagnostic categories and favors conceptualizing mental disorders as disorders of temporally patterned neural and behavioral activity. Such a shift may revolutionize both research methodologies and clinical practice standards.

The study’s limitations point to fertile ground for future inquiry. Although the sample size was robust, replication across diverse populations and clinical stages of schizophrenia is crucial to establish generalizability. Additionally, integrating neuroimaging data to directly link behavioral variability with underlying neural circuit function would deepen mechanistic understanding. Expanding longitudinal monitoring with real-world behavior sampling will also enhance ecological validity and patient relevance.

In sum, the findings reported by Chen et al. mark a pivotal advance in schizophrenia research, bringing into focus intra-subject variability in reward behavior as a dynamic biomarker intimately tied to symptom severity and disease progression. This paradigm holds promise not only for augmenting diagnostic precision but also for inspiring innovative, individualized interventions targeting the core motivational disturbances in schizophrenia. The ripple effects of this work are poised to reverberate across psychiatric research and clinical care in the coming decade.

The identification of intra-subject variability as a modifiable target may usher in a new chapter in schizophrenia management, bridging the longstanding translational gap between laboratory discoveries and bedside applications. Accentuating temporal dynamics in brain-behavior relationships promises richer characterizations of mental illness and paves the way for adaptive, real-time treatment paradigms. As such, this research exemplifies the power of integrative approaches coupling rigorous behavioral science with clinical acumen, heralding a future where mental health care is both more precise and proactive.

Subject of Research: The relationship between intra-subject variability in reward behavior and symptom severity in schizophrenia.

Article Title: Increased intra-subject variability in reward behavior relates to symptom severity in schizophrenia

Article References:
Chen, IF., Chan, YC., Liu, CM. et al. Increased intra-subject variability in reward behavior relates to symptom severity in schizophrenia. Schizophr 11, 108 (2025). https://doi.org/10.1038/s41537-025-00645-7

Image Credits: AI Generated

The APA Annual Meeting serves not merely as a conference; it stands as a platform where groundbreaking research intersects with everyday applications. With topics ranging from integrative approaches in treating mental health disorders to the utilization of lifestyle factors in promoting overall well-being, attendees will be privy to insights that can reshape practices and policies. The leadership of the APA recognizes the importance of adapting and integrating scientific advancements into clinical settings, highlighting an urgency to address mental health issues affecting diverse populations.

At the heart of the meeting lies a commitment to fostering robust discussions that empower mental health professionals and enhance patient care outcomes. With a lineup including nationally recognized experts, attendees will hear first-hand accounts of innovative research findings and policy changes that aim to improve mental health services. The agenda is meticulously designed to cover various topics encapsulating mental health education, clinical methods, and policy reform, thereby attracting an audience who is eager to assimilate new strategies into their practice.

An exciting addition this year is the opportunity for journalists to engage directly with APA leadership and mental health experts during scheduled media events. These interactions will allow for a deeper understanding of the most pressing mental health issues today and will provide a forum for discussing the implications of new research findings. Media attendees will gain exclusive insights into the APA’s annual Healthy Minds poll, which serves as a critical indicator of public sentiment towards mental health, and an embargoed study from the prestigious American Journal of Psychiatry.

Recognizing the diverse needs of the community it serves, the APA has also made arrangements for specialized sessions aimed at enhancing coverage of mental health issues within Latino communities. Scheduled for Sunday morning, this initiative underscores the APA’s ongoing commitment to inclusivity and representation in psychiatric discourse. Spanish-speaking journalists will have the opportunity to engage in discussions with leading APA experts who specialize in mental health within Latino populations, ensuring critical conversations take center stage.

Among the prominent speakers set to grace the meeting is APA President Ramaswamy Viswanathan, M.D., a figure renowned for his innovative contributions to psychiatry leadership and mental health advocacy. Alongside him, Marketa Wills, M.D., the APA’s CEO and Medical Director, will share insights about organizational initiatives aimed at enhancing mental health care delivery. The participation of Theresa Miskimen-Rivera, M.D., APA President-Elect, further reinforces the meeting’s credibility as a focal point for contemporary psychiatric dialogue.

Additionally, the event will see renowned personalities, such as tennis champion Venus Williams, sharing her perspectives on mental health and wellness through lifestyle choices. With publications listing her as a bestselling author, her contributions are expected to extend beyond athletics into the realms of resilience and mental strength, drawing parallels to mental health strategies in clinical settings. Her participation emphasizes the importance of lifestyle factors in maintaining positive mental and physical health.

Siddhartha Mukherjee, M.D., a prominent physician and researcher known for his eloquent writings on cancer biology, will lend expertise on the intersection of medical science and psychiatric practice. His ability to interweave narratives between scientific findings and clinical applications encourages an integrative approach that transcends conventional boundaries within mental health care systems.

Ellen Johnson Sirleaf, the first elected female president of Africa and a Nobel Peace Prize laureate, is expected to bring a global perspective to the discussions. Her experience and advocacy work illuminate the broader socio-political factors impacting mental health across nations, particularly in regions where access to mental health care remains significantly limited. By contextualizing her insights within the framework of developing mental health infrastructure, her presence at the meeting galvanizes the call for comprehensive mental health strategies globally.

The sessions at this event promise a thorough exploration of topics pertinent to current psychiatric research. The APA has made strides to ensure that participants can engage in meaningful discussions that foster collaboration and innovation among attendees. A detailed agenda, featuring a full listing of sessions, will be available to facilitate the navigation of a diverse array of topics, making it easier for participants to align their interests and professional development goals with available workshops and discussions.

Moreover, the meeting’s commitment to real-time research applications extends to on-site interactions in the Press Room, where journalists will have dedicated opportunities to engage with specialists and leadership. This segment not only creates an avenue for knowledge dissemination but also fosters ongoing dialogue about how new findings can shape public understanding and clinical practices regarding mental health issues.

In conclusion, the APA’s 2025 Annual Meeting embodies a pivotal moment in psychiatric dialogue, bridging gaps between research, policy, and clinical practice. The extensive programming combined with high-profile speakers is a testament to the event’s commitment to elevating the discourse surrounding mental health and enhancing the quality of care provided to those in need. With its focus on the interplay between lifestyle and mental well-being, the meeting not only seeks to inform but also inspires attendees to cultivate healthier communities through innovative psychiatric practices.

Subject of Research: Lifestyle for Positive Mental and Physical Health
Article Title: APA’s 2025 Annual Meeting: Pioneering the Future of Psychiatry
News Publication Date: October 2023
Web References:
References:
Image Credits:

Keywords: Psychiatry, Mental Health, Lifestyle Medicine, APA Annual Meeting, Research Collaboration, Mental Well-being, Public Health